These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 11466405)
1. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. Motta I; André F; Lim A; Tartaglia J; Cox WI; Zitvogel L; Angevin E; Kourilsky P J Immunol; 2001 Aug; 167(3):1795-802. PubMed ID: 11466405 [TBL] [Abstract][Full Text] [Related]
2. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821 [TBL] [Abstract][Full Text] [Related]
4. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
5. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Lopes L; Fletcher K; Ikeda Y; Collins M Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731 [TBL] [Abstract][Full Text] [Related]
6. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041 [TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240 [TBL] [Abstract][Full Text] [Related]
8. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966 [TBL] [Abstract][Full Text] [Related]
9. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334 [TBL] [Abstract][Full Text] [Related]
11. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316 [TBL] [Abstract][Full Text] [Related]
13. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054 [TBL] [Abstract][Full Text] [Related]
14. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. Kim CJ; Prevette T; Cormier J; Overwijk W; Roden M; Restifo NP; Rosenberg SA; Marincola FM J Immunother; 1997 Jul; 20(4):276-86. PubMed ID: 9220317 [TBL] [Abstract][Full Text] [Related]
15. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Chhabra A; Mehrotra S; Chakraborty NG; Mukherji B; Dorsky DI Eur J Immunol; 2004 Oct; 34(10):2824-33. PubMed ID: 15368298 [TBL] [Abstract][Full Text] [Related]
17. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691 [TBL] [Abstract][Full Text] [Related]
18. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Labarrière N; Bretaudeau L; Gervois N; Bodinier M; Bougras G; Diez E; Lang F; Gregoire M; Jotereau F Int J Cancer; 2002 Sep; 101(3):280-6. PubMed ID: 12209980 [TBL] [Abstract][Full Text] [Related]
19. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. Tabi Z; Moutaftsi M; Borysiewicz LK J Immunol; 2001 May; 166(9):5695-703. PubMed ID: 11313411 [TBL] [Abstract][Full Text] [Related]